[{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"6575bade-72bb-495f-8e06-eb39a449767d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639508","created_at":"2021-01-17T17:26:36.480Z","updated_at":"2024-07-02T16:35:44.723Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","source_id_and_acronym":"NCT01639508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" RET • ROS1 • KIF5B • AXL • NTRK","pipe":" | ","alterations":" RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion","tags":["RET • ROS1 • KIF5B • AXL • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-06-26"}]